Lyell Immunopharma (LYEL) Enterprise Value (2019 - 2025)
Historic Enterprise Value for Lyell Immunopharma (LYEL) over the last 7 years, with Q3 2025 value amounting to -$319.6 million.
- Lyell Immunopharma's Enterprise Value rose 2744.84% to -$319.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$319.6 million, marking a year-over-year increase of 2744.84%. This contributed to the annual value of -$370.5 million for FY2024, which is 3216.56% up from last year.
- As of Q3 2025, Lyell Immunopharma's Enterprise Value stood at -$319.6 million, which was up 2744.84% from -$276.8 million recorded in Q2 2025.
- In the past 5 years, Lyell Immunopharma's Enterprise Value ranged from a high of -$244.4 million in Q1 2021 and a low of -$824.5 million during Q2 2021
- Moreover, its 5-year median value for Enterprise Value was -$575.4 million (2023), whereas its average is -$521.9 million.
- Its Enterprise Value has fluctuated over the past 5 years, first plummeted by 35887.13% in 2021, then surged by 4364.1% in 2025.
- Quarter analysis of 5 years shows Lyell Immunopharma's Enterprise Value stood at -$614.8 million in 2021, then dropped by 4.12% to -$640.2 million in 2022, then grew by 14.67% to -$546.2 million in 2023, then soared by 32.17% to -$370.5 million in 2024, then rose by 13.74% to -$319.6 million in 2025.
- Its Enterprise Value was -$319.6 million in Q3 2025, compared to -$276.8 million in Q2 2025 and -$301.2 million in Q1 2025.